Single peptide that activates both the amylin and GLP-1 receptor families.
Reference facts
- Also known as
- NN1213, Amylin/GLP-1 unimolecular
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Single peptide that activates both the amylin and GLP-1 receptor families.
- Targets
- GLP-1R, Amylin receptors
- Indications under research or approved
- Obesity
- Regulatory status (reference entry)
- Investigational (Phase 2 oral, Phase 1b subcutaneous)
- Half-life
- ~7 days (subcutaneous formulation)
- Sequence notes
- Unimolecular dual amylin and GLP-1 receptor agonist; full sequence not publicly disclosed.
- Originator / sponsor
- Novo Nordisk
- First reported
- 2024
Primary References
Explore research articles about Amycretin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.